| This
may be why we are running~~I got this email last night Doug SPECIAL ALERT : We are sending this URGENT INVESTOR BULLETIN to our millions of subscribers IMMEDIATELY to allow investors the opportunity to accumulate a substantial position in this great stock. Advanced Viral Research Corp. (otcbb: ADVR) is the latest new pick, set to really move in near future. This company deserves your immediate attention. Stock Mogul Team found a new winner yet again! Advanced Viral Research Corp. (otcbb: ADVR) is primarily engaged in the production and marketing, promotion and sale of a pharmaceutical drug known by the trademark Reticulose. The current formulation of Reticulose is known as Product R now known as AVR118. Product R (AVR118) may be employed in the treatment of certain viral and autoimmune diseases such as human immunodeficiency virus (HIV); human papilloma virus (HPV), which causes genital warts and may lead to cervical cancer; cachexia (body wasting) in patients with solid cancers, leukemias and lymphomas, and rheumatoid arthritis. +-------------------------------------------+ Advanced Viral Research Corp. (otcbb: ADVR) Current price : $0.13 Short term target: $0.30 +-------------------------------------------+ Company completed the Phase I trial and submitted to the United States Food and Drug Administration (FDA) the results, which indicated that Product R was safe and well tolerated dermatologically in all the doses applied in the study. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. Our sources inside the company tell us that ADVR might be releasing the news on this subject fairly soon, probably within a few business days. This is a MASSIVE opportunity to get in before the stock shoots up. In February 2004, ADVR Secured $12 Million Financing !!! "I am pleased that with this funding, we can pursue our clinical trials in both Israel and the United States," said Eli Wilner, Chairman of the Board of ADVR. In March 2004, ADVR Granted a United States Patent for the Treatment of AIDS! ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as HIV and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. In April 2004, ADVR Appoints Dr. Carol Epstein as Acting Medical Director! "I am extremely pleased that Dr. Epstein has joined our team. Carol is known for her creative and strategic thinking," said Elma S. Hawkins, PhD, MBA, President and CEO of Advanced Viral Research Corp. "With her wealth of knowledge and expertise in clinical research and drug development, Carol is uniquely qualified to assist us in translating AVR118 into commercial realization. This marks the first time we have had someone with Dr. Epstein's level of expertise in clinical development at ADVR and demonstrates our commitment and focus in this area." This is just the tip of the iceberg and we expect a continuous flow of huge news announcements detailing the highly profitable chain of events to follow for ADVR in near future. We can state from our judicious research that we are not alone in viewing ADVR as one of those extremely rare opportunities where the impact of a major news event simultaneously boosts the value of a company while ultimately providing substantial reward for its shareholders. The Stock Mogul Team can't predict a long term target for ADVR, because noone knows what will happen when ADVR finds a treatment for AIDS/HIV !!!! This could skyrocket to $10.00 overnight; and then explode beyond our wildest dreams! |
| The
newsletter may carry more weight because it corresponds to the time frame the ADVR Management has said the Israeli results could be expected. That being Q2 of 2004, or now!! Company guidance plus newsletter = interest? Obviously! The results for just half of the study saw the stock go up 4.5 to 5X. Could be very interesting. Where's fasttrack? (Voluntary Disclosure: Position- Long) |
| The
reason for the uptick ?? Aside form the previously posted P&D
internet newsletter that probably reached a few million inboxes.....I
beleive it provides a great opportunity for the Dicke's to sell into the
pump with their previous shares, in order to finance the 3 million due
to ADVR on the 5th of May. If you look at the charts, the same thing
happened in the late part of January, prior to the original February 5th
financing..... Besides the obvious opportunity to invest in what will undoubtedly become the next miracle drug of the 21st century. I think the revolving financing plan, wherein they would make 150% on their investment within every 3 months is very attractive.....JMHO...... -kevtod - - - - - View Replies » |
| I
wonder if mbengineer will put this obvious hypster on ignore as he does
for his so-called bashers?? |
| Barry,
chart doesn't show anything odd. If you go back to my TA post from a few
days ago, ADVR fell right in line (luckily) with what I mentioned ...
That gap should close unless there's some awesome news out there... Regards, |
| I
had noticed that. Ironic considering Dicke is described as a friendly
investor by the company |
| Encouraging
that most trades are going off at the ask. Been over two months since
volume has broke ten million. This kind of volume has boded very well
for share price at least since the yearly high was reached. Kind of
unusual for Friday, isn't it? |
| Dougtherug:
I received the same alert. So far so good!: SPECIAL ALERT : "We are sending this URGENT INVESTOR BULLETIN to our millions of subscribers IMMEDIATELY to allow investors the opportunity to accumulate a substantial position in this great stock. Advanced Viral Research Corp. (otcbb: ADVR) is the latest new pick, set to really move in near future. This company deserves your immediate attention. Stock Mogul Team found a new winner yet again! Advanced Viral Research Corp. (otcbb: ADVR) is primarily engaged in the production and marketing, promotion and sale of a pharmaceutical drug known by the trademark Reticulose. The current formulation of Reticulose is known as Product R now known as AVR118. Product R (AVR118) may be employed in the treatment of certain viral and autoimmune diseases such as human immunodeficiency virus (HIV); human papilloma virus (HPV), which causes genital warts and may lead to cervical cancer; cachexia (body wasting) in patients with solid cancers, leukemias and lymphomas, and rheumatoid arthritis. +-------------------------------------------+ Advanced Viral Research Corp. (otcbb: ADVR) Current price : $0.13 Short term target: $0.30 +-------------------------------------------+ Company completed the Phase I trial and submitted to the United States Food and Drug Administration (FDA) the results, which indicated that Product R was safe and well tolerated dermatologically in all the doses applied in the study. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. Our sources inside the company tell us that ADVR might be releasing the news on this subject fairly soon, probably within a few business days. This is a MASSIVE opportunity to get in before the stock shoots up. In February 2004, ADVR Secured $12 Million Financing !!! "I am pleased that with this funding, we can pursue our clinical trials in both Israel and the United States," said Eli Wilner, Chairman of the Board of ADVR. In March 2004, ADVR Granted a United States Patent for the Treatment of AIDS! ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as HIV and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. In April 2004, ADVR Appoints Dr. Carol Epstein as Acting Medical Director! "I am extremely pleased that Dr. Epstein has joined our team. Carol is known for her creative and strategic thinking," said Elma S. Hawkins, PhD, MBA, President and CEO of Advanced Viral Research Corp. "With her wealth of knowledge and expertise in clinical research and drug development, Carol is uniquely qualified to assist us in translating AVR118 into commercial realization. This marks the first time we have had someone with Dr. Epstein's level of expertise in clinical development at ADVR and demonstrates our commitment and focus in this area." This is just the tip of the iceberg and we expect a continuous flow of huge news announcements detailing the highly profitable chain of events to follow for ADVR in near future. We can state from our judicious research that we are not alone in viewing ADVR as one of those extremely rare opportunities where the impact of a major news event simultaneously boosts the value of a company while ultimately providing substantial reward for its shareholders. The Stock Mogul Team can't predict a long term target for ADVR, because noone knows what will happen when ADVR finds a treatment for AIDS/HIV !!!! This could skyrocket to $10.00 overnight; and then explode beyond our wildest dreams! +-------------------------------------------+ Advanced Viral Research Corp. (otcbb: ADVR) Current price : $0.13 Short term target: $0.30 +-------------------------------------------+ Thank you for your Trust and Keep the Faith The Stock Mogul Team" ----------------------------- Great Day! LIA |
| ADVR
has only traded over 20 million shares twice in at least the last two
years. That email pump must have gotten out to quite a few traders to
drum up this much business. Either that or something's up. Guess we'll
know for sure come the middle of next week. I would imagine that if this
is a real move, they'll try to shake out the loose hands come Monday and
Tuesday. Especially is they close fairly high today. |
| Keith,
I'm LONG TERM, yet realize after well over 6 years from my advisers that
play the stock when you can and reap the profits that you never made if
you didn't and won't for a long time thereafter. Keep the majority of
ADVR if or because you believe in it. I do. Now watch the minority cult here bash me.... LIA |
| Good
philosophy when it comes to trading penny stocks. Wise not to wait to
long to cash in during any runup. I still believe advr has a move
nearing or over a buck left in her before the end of June, so I'm not
cashing in yet. If it costs me, so be it. Guess that just means I
believe. |
| Zenna-
ASCO doesn't specifically invite or ask a company to speak. They invite
scientific abstracts from their members who wish to attend the annual
meeting, and many of those abstracts are then selected for presentation,
as either a podium presentation or a poster presntation. The ADVR
presentation will be one of many from both companies and academic
institutions. The abstract was probably submitted by Jim D'Olimpio or
one of the other oncologists on the company's Scientific Advisory Board
who are members of ASCO. To answer your question, no ADVR hasn't presented at the ASCO National meeting in the past. |
Zenna,
I've been lurking here since 95 and I've never heard them mention ASCO
before or since. I don't think they would have had anything to present
till here lately anyway. It's the last hour of trading. Should find out
what the rally today was made of. Been consolidating fairly well, so I
don't expect a big retracement. Hope not anyway.
|
||
| 'has
ADVR ever been invited to speak in any capacity at ASCO in its
history??" --------------------- No, but each time ADVR has appeared at ANY meeting for a ANY presentation, it was also the first time ever for them at each organization's meeting. Each time predictions were always off the wall encouraging, as this one is, and each time the price either dropped or rose a little. However, with the spamming of the ADVR story as we witnessed today, I expect this will be hyped to the gills as it comes to that date, and the price WILL go higher. If there is nothing to follow it, it will also slide back again. Trader's dream scenario here, folks. Do not expect miracles here. - - - - - |
| Tells* Thanks for the response, and RE the asco forum, I realize that the acceptance (invitation) happens after submission...I only mention it because so many people have made the comment/inferred that there's nothing to ADVR's drug...that they're dragging it out just to fleece shareholders and make themselves rich, etc...I think ASCO presentation is BIGGIE (forum wise) and can't imagine that they'd attempt to put out B.S. data.... Regards, PS> gotta love the chart |
| Biotech
upstarts get injection of capital By Jim Hopkins, USA TODAY Posted 3/23/2004 SAN FRANCISCO — Merck, the pharmaceutical giant racing to replenish its drug pipeline, hatched a $100 million partnership in November with a tiny biotech start-up in Cambridge, Mass. Eli Lilly, another drugmaking stalwart, is plunging into the sizzling anti-impotence market ruled by Viagra with help from a young biotech near Seattle. Bristol-Myers Squibb, struggling to replace a cancer drug, is betting on a $2 billion deal with ImClone Systems — a biotech better known for its role in the Martha Stewart scandal. More slow-growth pharmaceutical firms like these are partnering with fast-growth biotechs for a dose of new drugs battling cancer and other illnesses. Lilly, for one, has launched about 100 partnerships, mostly with biotechs, many in the last five years. The trend underscores a power shift toward biotech in the drug and technology industries. Venture-capital investors are joining scientists in deciding what drugs get developed. Big pharmaceuticals are relying on biotechs to create new drugs for an aging population. And biotech is emerging as the next engine for innovation and jobs in the tech industry, long focused on computer chips and other traditional fare. But there are risks. Venture capitalists are pickier about the biotechs they finance than they were 10 years ago during the last boom. That means discoveries with extra-high risk may get overlooked — and so won't reach patients. "There's no question that good ideas don't get funded," says Jim Tullis, CEO of Tullis-Dickerson, a biotech VC firm. What's more, investors are betting on a highly regulated sector. The Food and Drug Administration slammed ImClone two years ago when it initially rejected its cancer drug. And the political debate over drug price controls makes VCs worry about paltry returns on start-up investments of $50 million or more. The industry has been an investors' roller coaster since the start. "Anyone who has tried to make projections has many times been wrong," says Alan Goldhammer, a regulatory official at the Pharmaceutical Research and Manufacturers of America trade group. Boom in biotech Yet there is powerful fuel for the shift to biotech: Big drug companies are slowing research to focus more on marketing other companies' discoveries. Years of work in biotech labs are yielding drugs proven to tackle cancer and other elusive targets. Even well-heeled investors such as Microsoft's Bill Gates are seizing on biotech as the tech industry's future. Venture-capital investors, who invest on behalf of institutions and rich individuals, poured more money into biotech in the third and fourth quarters than into any other industry — including software, the perennial favorite. The share of venture capital going to biotech surged from 14% in 2002 to 19% last year, higher than in the last financing boom. Biotech uses computer-powered genetic engineering to treat illnesses, create foods and improve manufacturing. Its high-tech promise is luring pharmaceuticals because of: • Dry pipelines. The number of new drugs approved annually by the FDA has tumbled 45% since 1996 — the last peak year. Ten years ago, traditional drugmakers were punching out 60 newly approved drugs a year. Biotech eked out just two to four, says Jim Broderick, a partner with Morgenthaler Ventures in Silicon Valley's Menlo Park. By last year, the two sectors were about even, at 20 each. "Big pharma has fallen dramatically, and the biotech industry has grown dramatically," Broderick says. That's caught pharmaceuticals' attention. For example, Lilly, running behind in developing an anti-impotence drug, formed a partnership in 1998 with Icos, the Seattle-area biotech, to develop and market Cialis. Icos, whose early investors include Microsoft's Gates, started work on Cialis in the early 1990s. The FDA approved Cialis in November — pitting Lilly against Pfizer's blockbuster Viagra. Experts debate why pharmaceuticals struggle to create new drugs. Their mammoth size may mean they've become too bureaucratic, so they chase only less-risky innovations more likely to produce a payoff, Broderick says. Also, they struggle to attract talent among biotech scientists who may think cutting-edge work can be better done at entrepreneurial start-ups. • Patent problems. Pharmaceuticals are losing exclusive blockbuster drugs — those generating annual revenue of $1 billion or more — as patents expire. That lets competitors swoop in to make generic versions, cutting into revenue. For example, Merck's top drug, the cholesterol-fighter Zocor, lost patent protection last year in Canada and some European nations. Since then, Zocor sales are down. Its USA patent expires in 2006. Zocor generated $5 billion, or about 23% of Merck's annual revenue, last year. • Merger mania. A wave of big pharmaceutical mergers and acquisitions in the past five years has left fewer competitors to gobble up, depleting a quick source of revenue growth. At least 20 deals have been announced or completed since 1999, including the record $115 billion combination in 2000 of Pfizer and Warner-Lambert. One of the rare deals more recently, still developing, is the $58 billion hostile bid announced in January by Sanofi-Synthelabo for its French rival, Aventis. • Big risk. Drug-development costs have soared as disease targets get more complex — and regulatory reviews grow longer. Development costs for all drugs, from lab to FDA approval, average $802 million per drug — more than double the cost in 1987, says the Pharmaceutical Research and Manufacturers of America. New drugs take as long as 15 years to reach FDA approval. That means big pharmaceuticals, under pressure from Wall Street to boost profits, are more skittish about investing in new drugs. That's another reason to cut risk by linking with biotech start-ups. Still, alliances have risks, too. That was the story at Bristol-Myers soon after it signed a marketing agreement for ImClone's cancer drug, Erbitux. The FDA, citing poor research data, rejected Erbitux in December 2001 — sending ImClone stock tumbling and threatening Bristol-Myers' $2 billion marketing deal with the biotech. Last month, acting on new data, the FDA finally approved Erbitux — boosting ImClone stock 29% in one day and winning Bristol-Myers a return on its gambit. It will get 61% of Erbitux revenue. The ImClone partnership is one of more than 190 that Bristol-Myers has signed with biotech and other firms. A higher bar Risks, amid higher investment costs, are one reason VCs are now choosier about biotechs. Last year, they invested an average $11.2 million per biotech deal, nearly three times the average 10 years ago. More VCs are looking for biotechs with drugs deeper in development. The best candidates are those close to, or already in, the first phase of human testing, says James Golden, research vice president at Life Science Insights, an industry tracker. A recent example: GenPath Pharmaceuticals — Merck's new biotech partner. Founded by two Harvard University scientists, GenPath hopes to begin Phase 1 testing next year, says CEO Tuan Ha-Ngoc. That timetable attracted eight VCs and several private investors. They pumped $42.7 million into the Cambridge company in October. The Merck partnership came the following month. Merck has ramped up the number of such partnerships in the last year. It has more than 80, mostly with biotechs; 47 were formed last year. Ha-Ngoc says GenPath is talking to other pharmaceuticals about deals. GenPath's workforce is growing, underlining biotech's job-building potential. The company, with 65 employees, expects to add 35 by the end of the year. Certainly, these partnerships aren't a one-way street. Biotechs gain pharmaceuticals' expertise in guiding drugs through the labyrinth of human testing, which can account for half of development time. "It's very difficult to clear all the hurdles," says Icos CEO Paul Clark. Moreover, Lilly and other pharmaceuticals are skilled at marketing and distribution. Icos has 165 newly hired sales representatives. Lilly will assist with its own sales force. The growing number of partnerships is luring more investors. New Enterprise Associates, an influential VC firm in Silicon Valley, just raised $1.1 billion partly for health investments. Venrock Associates, the Rockefeller family's investment arm, raised $550 million in January. About 30% will go to biotech and other health start-ups. Traditional tech is still profitable, but product life cycles are shorter, reducing investor returns. Yet a biotech with a successful drug can generate $500 million in annual revenue — with 95% gross profit margins for years, says Bryan Roberts, Venrock general partner in Menlo Park. "Like getting a winning lottery ticket," he says. ---------------- Biotech's risks Venture capital investors last year pumped $3.4 billion into biotech start-ups, a risky industry barely reaching adolescence. Biotech has fewer than 1,500 companies and fewer than 200,000 workers. Only about 100 biotech drugs reached the market in the past 30 years. Genentech and Amgen are among the few big, profitable biotechs whose names are well-known. Many biotech drugs fail, leaving the industry swimming in red ink. Global losses in 2002, the most recent year available, more than doubled to $12.5 billion from $5.8 billion in 2001, Ernst & Young says. Too many companies are chasing too few investor dollars, the consultant says. By Jim Hopkins Find this article at: http://www.usatoday.com/money/industries/health/drugs/2004-03-23-biotech_x.htm |
| NO
never according to shaggy dog. This is one the real major meetings that
invited the drug results to be presentedin a poster. The answer will be
the responce when the poster is presented and the questons as Dr."D"
will get. The size of the audience will also be important. This could be
a turning point. |
| Thanks,
mbengineer. I'll never understand how anyone can not be excited about an
abstract on AVR118 that has been selected for presentation at The
American Society of Clinical Oncology's (ASCO). This is a great opportunity for ADVR and once again puts us in front of the scientific community and is another real plus for AVR118. It's the kind of exposure that we always wanted and are finally able to enjoy. Yes, this can be a real turning point, as you say. Absolutely! To so many here: "Oh yea of little faith". Best to you! LIA |
| Hello
Mb,Well this late afternoon on CNBC they were talking about The ASCO
meeting in june,they way CNBC was talking it is a BIG SHINDIG!!They also
mentioned that alot companys announce thier BIG FINDINGS at the ASCO
meeting!!CNBC also stated that GENATEC and IMCLONE are to announce some
biggie thing related to CANCER and expect a BIG RISE in PPS!!Well
MAYBE,JUST MAYBE this will be the catalist platform for ADVR!!....GO GO
GO ADVR.....Aven1 (Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy) |
| mbengineer.....you
say, concerning the ASCO meeting...."This is one the real major
meetings that invited the drug results to be presentedin a poster." If I am reading your above sentence correctly....are you saying the company WAS INVITED TO PRESENT THE FINDINGS OF DRUG RESULTS? W.H.A.T. R.E.S.U.L.T.S??????? Are you suggesting the Phase I/II results on the 30 patients are completed.....completed enough for the ASCO to know enough surrounding the findings to INVITE ADVR to the conference? This isn't making sense! Would not the company have to initiate the "invitation" by stating to ASCO the data from the "completed" Israel trials? If the STUFF to be presented (poster or other) at the ASCO meeting, is to be TOP SECRET up until the conference....how in the devil did ASCO know to invite ADVR? According to the last SEC report, they were still in need of a few more patients, in order to complete the trial???? How do you get invited to an ASCO meeting (which was announced via PR a few weeks ago) and still not have "the entire 30 patients"?? UNLESS.....they are using the Weizmann results -- which have nothing to do with the above-mentioned!! Geez....this stuff could drive a person to eat Chinese food!!....LOL |
| Also,
it's my understanding the ASCO is about cancer, not HIV - and there have
been NO completed studies done with cancer patients that WE know about. This kind of obfuscation is typical of this company. |
| Their
is a reason the stock went up Red Hearing News Alert SAguribup. Has a
alert on advr. "ADVR is the latest new pick, set to really move in
near future". " ADVR118 is in clinical trials in Israel for the treatment of cahesia(body wasting) in patients with AIDS.Our sources inside the company tell us that Advr might be releasing the news on this subject fairly soon, probably within a few business days" - - - - - |
| wasting
with cachexia is what kills you when you have cancer |
| tmclion1:
Thanks for that! I received a Special Alert today on ADVR that others
did and that we posted about. It's always interesting getting these
alerts and just investigating them out of curiosity, but it's terrific
seeing ADVR in one you receive. I hope they're right. We'll soon know. I'm all for it and can only say good luck to all of us. LIA |
| That's
right Billblue! And I'll bet there's a lot we haven't heard about the
success in cancer cachexia patients as well. |
| Bernie,
I gotta' tell you, I'm not so sure the run now is due to the ASCO
conference; I tend to think Kev's theory may be "right on"
concerning the Dickies' deal! Not so sure if, what I believe to be true,
it's a good thing.... (although next time around in 3 months it may be a
good thing for trading), it makes a shareholder wonder, how much of the
PPS is, indeed, controlled.....and BY WHOM???? Night, night!! |
| This
POS has been soooo pumped.....that my local buddies have given me a
"HOT STOCK TIP"...... ....ADVR...... What up wit' dat ????..... |
| Kevtod,
How do you buy shares at .20 sell at less than .20 and make a profit? I do think the Dicke's have a huge interest in the share price but I don't think it's their shares moving this. If anything the company is moving like mad to get the pps up so Dicke doesn't hesitate on the next 3M due 5/15. He bought the 1st round when the market price was .15 it would not be good to have him buy another round at that price or lower 3 months later. JMHO! |
| Penny-
Go read the contract...the Dicke's bought options at .20 ....eom |
| Kev,
just remember the herd is usually wrong, so the more disgusted longs are
with the stock, the better the chances are that we're heading up!! MOO (its worked well many many times for me!) Regards, (Voluntary Disclosure: Position- Long) |